Synthetaic Forms Five-Year Strategic Partnership With Microsoft for Next-Generation AI Data and Cloud Solutions
Synthetaic will take advantage of Microsoft’s investment of significant cloud GPU compute access to fuel…
Synthetaic will take advantage of Microsoft’s investment of significant cloud GPU compute access to fuel…
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC…
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC…
– $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in…
– $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in…
Celularity to provide research support for Regeneron’s targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy…
Celularity to provide research support for Regeneron’s targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy…
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage…
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage…
Digipath, Inc. High capacity LCMS-QQQ for testing pesticides Lab Operations has Seen a Consistent Uptick…
Digipath, Inc. High capacity LCMS-QQQ for testing pesticides Lab Operations has Seen a Consistent Uptick…
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or…
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting…
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting…
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S….
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S….
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
Independent Safety Committee approves next cohort dosing of RECCE® 327 (R327) at two faster infusion…